Interestingly, artesunate is currently evaluated as a therapeutic agent for Friedreich’s ataxia (FA), suggesting that it might be also relevant for the treatment of other similar disorders, including SCA1 [75]. Here, ATXN1 is linked to Friedreich ataxia.